<img alt="" src="https://secure.perk0mean.com/184504.png" style="display:none;">
Skip to content
Request a Demo
TRIAL TRENDS™ PODCAST

Evolving Perception of Pharma Part 2

About the Episode

  • Summary

    Since the onset of the COVID-19 pandemic, the pharmaceutical industry has been under intense scrutiny, and social media is driving much of its public perception in today's environment. In part 1 of this episode, Azadeh Nolan, tells her personal experience on working within the industry during COVID and being a source of information for her closest friends, family and even the general public at large.

  • Show Notes

    Welcome to Trial Trends™, a podcast brought to you by 4G Clinical! Host Kathleen Greenough, VP of Commercial Operations at 4G Clinical, welcomes on guests from all over to tackle big ideas, challenge the status quo, and bring fresh perspectives to a rapidly changing world of clinical trials. Join us as we disrupt the old ways of thinking and discover the newest trial trends! Tune into today’s episode as we dive into part 2 of our discussion around the evolving perception of Pharma with Azadeh Nolan. Make sure you listen to part 1 to find out more about her experiences. Today, we get a glimpse behind the curtain on planning, developing, and executing trials in the pharmaceutical industry.

    Kathleen kicks off this episode by asking about the by-in that is required for the parents of children involved in trials. How do they get the trust and messaging necessary? Azadeh speaks to looking at the impacts of the trials therapeutically, socially, and psychologically. While trust must be earned, we also must have the expectation that we will be continual learners.Parents’ trust is crucial in these trials to give their children the allergens that are otherwise deadly to them.

    Continuing the conversation, Kathleen asks a second question, and it is all about the checks and balances in this industry. Learn about the post-market studies to ensure safety, and the desire to keep improving through continual monitoring and advancements. What systems exist to double check a trial and the data requirements? Listen in on their conversation as they chat about the vast number of drugs that are not approved, or that have been recalled due to this continued research. Once a drug is through the trial phase, what happens? They discuss the rigorous process and verification of efficacy that occurs. Kathleen also asks about the “black box” of clinical development. Azadeh discusses the concept and process of playing out all the outcomes and the possibility of having to start over if the outcomes are not advantageous. There are countless years of research behind the drugs we see at a pharmacy.

    While the media and societal misconceptions play into our everyday thinking about these topics, Azadeh shares what she thinks needs redefined. Learn about the power of data and why we should not expect perfection. It is alright for things to change, Azadeh reminds listeners that it is just biology, working towards perfection. As the conversation draws to a close, they chat about where are we headed and what have we done right so far. See the empathy and emphasis on humanity that proves a strength in today’s world. We have done it all together!

Since the onset of the COVID-19 pandemic, the pharmaceutical industry has been under intense scrutiny, and social media is driving much of its public perception in today's environment. In part 1 of this episode, Azadeh Nolan, tells her personal experience on working within the industry during COVID and being a source of information for her closest friends, family and even the general public at large.

Welcome to Trial Trends™, a podcast brought to you by 4G Clinical! Host Kathleen Greenough, VP of Commercial Operations at 4G Clinical, welcomes on guests from all over to tackle big ideas, challenge the status quo, and bring fresh perspectives to a rapidly changing world of clinical trials. Join us as we disrupt the old ways of thinking and discover the newest trial trends! Tune into today’s episode as we dive into part 2 of our discussion around the evolving perception of Pharma with Azadeh Nolan. Make sure you listen to part 1 to find out more about her experiences. Today, we get a glimpse behind the curtain on planning, developing, and executing trials in the pharmaceutical industry.

Kathleen kicks off this episode by asking about the by-in that is required for the parents of children involved in trials. How do they get the trust and messaging necessary? Azadeh speaks to looking at the impacts of the trials therapeutically, socially, and psychologically. While trust must be earned, we also must have the expectation that we will be continual learners.Parents’ trust is crucial in these trials to give their children the allergens that are otherwise deadly to them.

Continuing the conversation, Kathleen asks a second question, and it is all about the checks and balances in this industry. Learn about the post-market studies to ensure safety, and the desire to keep improving through continual monitoring and advancements. What systems exist to double check a trial and the data requirements? Listen in on their conversation as they chat about the vast number of drugs that are not approved, or that have been recalled due to this continued research. Once a drug is through the trial phase, what happens? They discuss the rigorous process and verification of efficacy that occurs. Kathleen also asks about the “black box” of clinical development. Azadeh discusses the concept and process of playing out all the outcomes and the possibility of having to start over if the outcomes are not advantageous. There are countless years of research behind the drugs we see at a pharmacy.

While the media and societal misconceptions play into our everyday thinking about these topics, Azadeh shares what she thinks needs redefined. Learn about the power of data and why we should not expect perfection. It is alright for things to change, Azadeh reminds listeners that it is just biology, working towards perfection. As the conversation draws to a close, they chat about where are we headed and what have we done right so far. See the empathy and emphasis on humanity that proves a strength in today’s world. We have done it all together!

See Who’s Talking

LIBBI RICKENBACHER

AZADEH NOLAN

LIBBI RICKENBACHER

Libbi has over 15 years of experience in the field of life sciences, and is an e-clinical RTSM solutions subject matter expert. Her experience lies at building and managing accounts, clients, and strategic initiatives.

AZADEH NOLAN

Azadeh is a true Clinical Supplies pioneer with nearly 20 years of experience in pharma, dedicated to and with continuous accomplishments building and growing the industry’s Clinical Supply Chain Operations landscape as it’s seen today.